Switch theme
Sign up to access all valuation multiples
S Biomedics Co Ltd researches and develops cell therapies for regenerative biomedicine. It owns two platform technologies: Functionally Enhanced Cell Spheroid and Targeted Embryonic Stem Cell Differentiation for developing cell therapy products that overcome the limitations of existing cell therapy products.
2005
n/a
LTM Revenue n/a
LTM EBITDA n/a
$167M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
S Biomedics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, S Biomedics achieved revenue of $9.4M and an EBITDA of -$2.2M.
S Biomedics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See S Biomedics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $8.9M | $9.4M | XXX | XXX | XXX |
| Gross Profit | $4.2M | $4.5M | XXX | XXX | XXX |
| Gross Margin | 47% | 48% | XXX | XXX | XXX |
| EBITDA | -$2.7M | -$2.2M | XXX | XXX | XXX |
| EBITDA Margin | -30% | -24% | XXX | XXX | XXX |
| Net Profit | -$4.3M | -$5.1M | XXX | XXX | XXX |
| Net Margin | -48% | -55% | XXX | XXX | XXX |
| Net Debt | $6.2M | $6.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, S Biomedics's stock price is KRW 21350 (or $15).
S Biomedics has current market cap of KRW 251B (or $171M), and EV of KRW 246B (or $167M).
See S Biomedics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $167M | $171M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, S Biomedics has market cap of $171M and EV of $167M.
S Biomedics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate S Biomedics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for S Biomedics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $167M | XXX | XXX | XXX |
| EV/Revenue | 17.9x | XXX | XXX | XXX |
| EV/EBITDA | -75.9x | XXX | XXX | XXX |
| P/E | -37.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -47.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpS Biomedics's NTM/LTM revenue growth is n/a
S Biomedics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, S Biomedics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate S Biomedics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for S Biomedics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -24% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -17% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 9% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 43% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 88% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
S Biomedics acquired XXX companies to date.
Last acquisition by S Biomedics was XXXXXXXX, XXXXX XXXXX XXXXXX . S Biomedics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was S Biomedics founded? | S Biomedics was founded in 2005. |
| Where is S Biomedics headquartered? | S Biomedics is headquartered in South Korea. |
| Is S Biomedics publicy listed? | Yes, S Biomedics is a public company listed on KRX. |
| What is the stock symbol of S Biomedics? | S Biomedics trades under 304360 ticker. |
| When did S Biomedics go public? | S Biomedics went public in 2023. |
| Who are competitors of S Biomedics? | Similar companies to S Biomedics include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of S Biomedics? | S Biomedics's current market cap is $171M |
| What is the current revenue growth of S Biomedics? | S Biomedics revenue growth between 2023 and 2024 was 5%. |
| Is S Biomedics profitable? | Yes, S Biomedics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
